thalidomide has been researched along with Bone Marrow Neoplasms in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is an antiangiogenic drug that produces a response rate ranging from 32 to 64% in patients with refractory/relapsed multiple myeloma (MM)." | 7.72 | Extramedullary multiple myeloma escapes the effect of thalidomide. ( Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 7.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| "Thalidomide is an antiangiogenic drug that produces a response rate ranging from 32 to 64% in patients with refractory/relapsed multiple myeloma (MM)." | 3.72 | Extramedullary multiple myeloma escapes the effect of thalidomide. ( Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 3.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayyalu, TK | 1 |
| Issa, M | 1 |
| Rosiñol, L | 1 |
| Cibeira, MT | 1 |
| Bladé, J | 1 |
| Esteve, J | 1 |
| Aymerich, M | 1 |
| Rozman, M | 1 |
| Segarra, M | 1 |
| Cid, MC | 1 |
| Filella, X | 1 |
| Montserrat, E | 1 |
| Avigdor, A | 1 |
| Raanani, P | 1 |
| Levi, I | 1 |
| Hardan, I | 1 |
| Ben-Bassat, I | 1 |
3 other studies available for thalidomide and Bone Marrow Neoplasms
| Article | Year |
|---|---|
Lenalidomide-associated arterial thrombosis in a patient with JAK2 positive atypical myeloproliferative neoplasm.
Topics: Aged; Bone Marrow Neoplasms; Fatal Outcome; Female; Humans; Immunologic Factors; Janus Kinase 2; Len | 2017 |
Extramedullary multiple myeloma escapes the effect of thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow Neoplasms; Dose-Response Relati | 2004 |
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
Topics: Adult; Bone Marrow; Bone Marrow Neoplasms; Brain Neoplasms; Disease Progression; Humans; Male; Middl | 2001 |